BTBD14B Antibody (C-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q96RE7 |
---|---|
Clone Names | 70716032 |
Gene ID | 112939 |
---|---|
Other Names | Nucleus accumbens-associated protein 1, NAC-1, BTB/POZ domain-containing protein 14B, NACC1, BTBD14B, NAC1 |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP1493b was selected from the C-term region of human BTBD14B. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | NACC1 |
---|---|
Synonyms | BTBD14B, NAC1 |
Function | Functions as a transcriptional repressor. Seems to function as a transcriptional corepressor in neuronal cells through recruitment of HDAC3 and HDAC4. Contributes to tumor progression, and tumor cell proliferation and survival. This may be mediated at least in part through repressing transcriptional activity of GADD45GIP1. Required for recruiting the proteasome from the nucleus to the cytoplasm and dendritic spines. |
Cellular Location | Nucleus. Cytoplasm. Note=Distribution in the cytoplasm is dependent on phosphorylation. |
Tissue Location | Overexpressed in several types of carcinomas including ovarian serous carcinomas. Expression levels positively correlate with tumor recurrence in ovarian serous carcinomas, and intense immunoreactivity in primary ovarian tumors predicts early recurrence. Up-regulated in ovarian carcinomas after chemotherapy, suggesting a role in development of chemotherapy resistance in ovarian cancer. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
BTBD14B functions as a transcriptional corepressor in neuronal cells through recruitment of HDAC3 and HDAC4. In humans the protein is upregulated in a number of carcinomas and is localized in discrete nuclear bodies that correlate with tumour recurrence.
References
Nakayama,K., Cancer Res. 67 (17), 8058-8064 (2007)Davidson,B., Hum. Pathol. 38 (7), 1030-1036 (2007)Nakayama,K., Proc. Natl. Acad. Sci. U.S.A. 103 (49), 18739-18744 (2006)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.